IOVA SEC Filings - Iovance Biotherp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access SEC filings for Iovance Biotherapeutics (IOVA), including 10-K, 10-Q, and 8-K reports, along with insider trading forms. The platform features AI-powered summaries, impact scoring, and sentiment analysis for each document. Recent filings highlight State Street's passive stake, Iovance affirming its 2025 Amtagvi revenue guidance, and details on officer RSU vesting and tax withholdings.
Why Is Iovance Biotherapeutics, Inc. (IOVA) Stock Down Today?
Iovance Biotherapeutics, Inc. (IOVA) stock is down -0.58% today, trading at $3.43 with lower than average volume. Despite this short-term dip, technical indicators show the stock trading above its 50-day and 200-day moving averages, suggesting underlying strength. Analyst sentiment remains bullish, and Meyka's AI assigns it a 'B' grade, forecasting potential returns in the short term.
Iovance Biotherapeutics (IOVA) Is Down 6.5% After FDA Questions Amtagvi Marketing Claims Has The Bull Case Changed?
Iovance Biotherapeutics (IOVA) experienced a 6.5% drop after the FDA questioned the marketing claims for its drug Amtagvi, specifically regarding overall survival data. This regulatory scrutiny prompts a re-evaluation of Iovance's investment narrative, as the company's growth hinges on successful commercialization and communication of Amtagvi's efficacy. The incident highlights the challenges Iovance faces in balancing promotional efforts with regulatory compliance, particularly as it expands into broader indications and international markets.
A Look At Iovance Biotherapeutics (IOVA) Valuation After FDA Concerns Over Amtagvi Marketing Practices
Iovance Biotherapeutics is facing FDA scrutiny over promotional materials for its skin cancer treatment, Amtagvi, which could mislead about its effectiveness. Despite a "58% Undervalued" narrative and a strong pipeline, the company is still loss-making. The current valuation of $3.51 raises questions about whether it accurately reflects the execution and regulatory risks or is already pricing in future growth.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) reported a wider loss than anticipated in Q2 2026, with revenue also falling short of Zacks Consensus Estimate. Despite the earnings miss, the company's shares gained 1.4% in after-hours trading, suggesting investors may be focusing on other aspects of the earnings call or future prospects. The report highlights the financial performance of the biopharmaceutical company during the quarter.
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
Iovance Biotherapeutics (IOVA) reported a Q2 loss per share of $0.62, which was narrower than the Zacks Consensus Estimate but wider than the year-ago loss. The company's revenue for the quarter was $0.85 million, significantly missing both the consensus estimate and the prior-year figure. Despite the revenue miss, the company's shares are up 15.6% year-to-date, outperforming the industry's 7.6% decline.
Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help (NASDAQ:IOVA)
Iovance Biotherapeutics (IOVA) is showing strong momentum with its Amtagvi product, reporting significant Q4'25 revenue and anticipating remarkable growth in 2026, despite not yet providing formal guidance. The company faces potential competition in melanoma from REPL’s RP1 but is expanding its pipeline into new indications like NSCLC and sarcoma, which could drive future growth. IOVA aims to extend its cash runway into Q3'27 through revenue growth, margin improvements, and cost reductions, managing a high cash burn.
Iovance Biotherapeutics, Inc. $IOVA Stock Position Raised by Mirador Capital Partners LP
Mirador Capital Partners LP significantly increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 100.9% in Q4, acquiring over half a million additional shares. This move brings their total holdings to 1,034,544 shares, valued at approximately $2.82 million. Despite the company's continued unprofitability, it surpassed quarterly earnings and revenue expectations, while analyst ratings remain mixed with a consensus "Hold" but varying price targets.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of "Hold" by Brokerages
Iovance Biotherapeutics (NASDAQ:IOVA) has received an average "Hold" recommendation from twelve brokerages, with an average 12-month price target of $8.88. Despite beating recent quarterly estimates for EPS and revenue, the company remains unprofitable with analysts projecting a negative EPS for the current fiscal year. Institutional investors, including Vanguard and State Street, have increased their holdings, with institutions owning about 77.03% of the company.
Vanguard (IOVA) shows 0 shares after Jan 12, 2026 realignment
The article reports that The Vanguard Group's latest Schedule 13G/A filing for Iovance Biotherapeutics (IOVA) shows 0 shares and 0% ownership. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries now report beneficial ownership separately. The filing clarifies that Vanguard no longer holds beneficial ownership over securities held by these disaggregated subsidiaries.
Iovance Biotherapeutics (NASDAQ:IOVA) Rating Increased to Hold at Truist Financial
Truist Financial has upgraded Iovance Biotherapeutics (NASDAQ:IOVA) to a "hold" rating. The biotechnology company recently beat earnings and revenue estimates but remains unprofitable, though institutional investment in IOVA has significantly increased. The average price target from analysts for IOVA is $8.88, with a consensus "Hold" rating.
Is Iovance Biotherapeutics (IOVA) Offering A Compelling Opportunity After Recent Price Swings?
This article analyzes Iovance Biotherapeutics (IOVA) after recent price fluctuations, examining its valuation through Discounted Cash Flow (DCF) and Price-to-Sales (P/S) ratios. While the DCF model suggests significant undervaluation with a potential 84.6% discount, the P/S ratio indicates the stock is overvalued compared to Simply Wall St's "Fair Ratio" at 5.66x versus 4.16x. The report encourages investors to use "Narratives" on Simply Wall St to align their personal assumptions with forecast numbers and assess the stock's attractiveness.
Iovance Biotherapeutics Announces Upcoming Board Member Retirement
Iovance Biotherapeutics announced that board member Wendy Yarno will retire in June 2026 and will not seek re-election. The company clarified that her decision was not due to any disagreements regarding operations, policies, or practices. This change is viewed as an orderly refresh of board membership, with analysts currently rating IOVA as "Hold" with a $4.00 price target.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 3,400 shares of its common stock to one new non-executive employee on March 19, 2026. This award was made under the company's Amended and Restated 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.87 and will vest over a three-year period, tied to continued employment.
A Look At Iovance Biotherapeutics (IOVA) Valuation After Pipeline And Regulatory Updates At Barclays Healthcare Conference
Iovance Biotherapeutics (IOVA) recently presented its growth plans, early sarcoma data, and regulatory updates for Amtagvi at the Barclays Healthcare Conference. Despite recent share price gains, long-term returns have been weaker. The article analyzes IOVA's valuation, finding it potentially undervalued by some metrics, yet cautions against potential regulatory setbacks and dependence on a single therapy like Amtagvi.
Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi
Analyst sentiment remains strong for Iovance Biotherapeutics (IOVA) with a consensus price target of $9.50, suggesting a potential upside of 135.15%. The company is expanding the U.S. rollout of its melanoma drug, Amtagvi, which is projected to generate at least $1 billion in peak U.S. sales, and is also advancing pipeline products in lung cancer and sarcoma. Regulatory decisions for Amtagvi in the UK and Australia are anticipated in the first half of 2026.
Iovance Biotherapeutics board member Wendy Yarno to retire after current term
Wendy Yarno, a board member of Iovance Biotherapeutics, will retire after her current term ends at the annual meeting in June 2026. Her decision is not due to any disagreement with the company's operations or policies. This announcement follows a strong financial performance for the company in Q4 2025 and positive early clinical trial data for its drug lifileucel.
Iovance Biotherapeutics Announces Upcoming Board Member Retirement
Iovance Biotherapeutics announced that board member Wendy Yarno will retire from its Board of Directors and will not seek re-election at the company's annual meeting in June 2026. This decision is framed as a routine board transition, with the company emphasizing no disagreements regarding operations, policies, or practices. The stock (IOVA) currently has a Hold rating from analysts with a $4.00 price target, and TipRanks' AI Analyst also gives it a Neutral rating due to strong technical momentum and positive earnings signals, offset by weak financial performance.
Form 8K Iovance Biotherapeutics Inc For: 20 March
This article announces the filing of a Form 8K by Iovance Biotherapeutics Inc on March 20, 2026. The 8K filing is a report of material events or corporate changes at a company that could be of importance to shareholders or the Securities and Exchange Commission (SEC). The article itself is brief, primarily serving as a notification of the filing.
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced that board member Wendy Yarno will retire and not seek re-election at the company's annual meeting, expected in June 2026. Ms. Yarno will continue her role as director until the annual meeting. The company stated that her decision is not due to any disagreement with Iovance's operations, policies, or practices, and publicly thanked her for her service.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced it granted inducement stock options for 3,400 shares to a new non-executive employee under its Amended and Restated 2021 Inducement Plan. The options, with an exercise price of $3.87, vest over three years following Nasdaq Listing Rule 5635(c)(4) requirements. This action reflects the company's continuous efforts to attract talent in its mission to develop and deliver TIL therapies for cancer patients.
New Iovance hire gets stock options priced at $3.87 a share
Iovance Biotherapeutics has granted inducement stock options for 3,400 shares to a new non-executive employee. The options were priced at $3.87 per share, matching the closing price on the grant date of March 19, 2026, and will vest over three years. This grant is part of the company's Amended and Restated 2021 Inducement Plan and is considered routine corporate housekeeping in the context of recent significant clinical and earnings milestones.
Form 8K Iovance Biotherapeutics Inc For: 20 March
This article reports on an 8K filing by Iovance Biotherapeutics Inc on March 20. It includes a disclaimer about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate. The article also provides general advice to investors to consider their objectives and seek professional advice before trading.
Iovance Biotherapeutics (IOVA) Is Down 25.3% After Strong Early TIL Sarcoma Data Spurs Registrational Trial - What's Changed
Iovance Biotherapeutics saw its stock drop despite strong early data for its TIL therapy, lifileucel, in advanced soft tissue sarcomas, leading to plans for a registrational trial. While these results suggest a potential expansion of its platform beyond melanoma, the company still faces significant financial pressure from ongoing losses and its dependence on Amtagvi revenue in melanoma. Analysts highlight the need for revenue growth and profitability, with current forecasts predicting a substantial increase in earnings by 2028.
Long Focus Capital Management LLC Reduces Stock Position in Iovance Biotherapeutics, Inc. $IOVA
Long Focus Capital Management LLC significantly reduced its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 22.9% in the third quarter, selling over 2.7 million shares. Despite this, other institutional investors like Squarepoint Ops LLC and Invenomic Capital Management LP increased their positions, and analysts maintain a "Hold" rating with an average price target of $8.88. Iovance recently surpassed quarterly revenue and EPS estimates but remains unprofitable.
Invenomic Capital Management LP Buys 2,246,945 Shares of Iovance Biotherapeutics, Inc. $IOVA
Invenomic Capital Management LP has increased its stake in Iovance Biotherapeutics (NASDAQ:IOVA) by 27.1%, purchasing an additional 2,246,945 shares. This acquisition brings their total holding to 10,541,608 shares, representing about 2.66% of the company's stock, valued at approximately $22.9 million. Other major institutions like Bank of America, UBS Asset Management, and Goldman Sachs also raised their positions, leading to institutional investors owning about 77.03% of Iovance.
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook
Iovance Biotherapeutics (NASDAQ: IOVA) has seen its stock decline by 13.12% recently, facing significant financial challenges with a net loss of $71.9 million in Q4 2025 due to high research expenses. The company's future performance hinges on strategic shifts to reduce costs, enhance revenue, and manage a negative EBIT margin, as investors closely monitor its path to profitability. Analysts emphasize the need for operational improvements and potential partnerships to regain market confidence.
235,000 RSUs granted to Iovance (NASDAQ: IOVA) interim CEO Frederick Vogt
Iovance Biotherapeutics (NASDAQ: IOVA) has granted 235,000 restricted stock units (RSUs) to its interim CEO and General Counsel, Frederick G. Vogt. The RSUs, detailed in an SEC Form 4 filing, will vest over three years, with one-third vesting after one year and the remainder in quarterly installments over the subsequent two years, contingent on Vogt's continued employment. This grant is part of his compensation, aligning his interests with the company's performance.
IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant
IOVANCE BIOTHERAPEUTICS, INC. (NASDAQ: IOVA) Chief Financial Officer, Corleen M. Roche, was granted 132,200 restricted stock units (RSUs) as equity compensation. These RSUs vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remainder vesting quarterly over the subsequent two years, contingent on her continued employment. This transaction was reported in a Form 4 SEC filing.
Iovance (NASDAQ: IOVA) COO awarded 117,500 RSUs over 3 years
Iovance Biotherapeutics' Chief Operating Officer, Igor Bilinsky, was granted 117,500 restricted stock units (RSUs) according to a recent Form 4 SEC filing. Each RSU represents one share of common stock and the award vests over three years: one-third after the first year, and the remainder in eight quarterly installments. This compensation ties Bilinsky's interests to the company's long-term equity value and continued service.
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum
Iovance Biotherapeutics (IOVA) has seen significant recent share price momentum, with a 103% return over the past month, drawing investor attention to its commercial-stage cell therapy despite ongoing net losses. The company is considered 38.6% undervalued by some analyses, with a fair value of $8.35 based on future cash flows and anticipated improvements from operational streamlining and workforce reduction. However, its current P/S ratio of 8x, while cheaper than the industry average, is still above a fair ratio of 4.5x, suggesting potential valuation risk if growth expectations are not met.
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target
Iovance Biotherapeutics Inc. (IOVA) reached a new 52-week high after an investment firm doubled its price target for the stock, with UBS raising its target to $4 from $2 while maintaining a "neutral" rating. Wells Fargo maintained a "buy" recommendation and a $14 price target. The company reported a 60.6% jump in total revenues to $263.5 million for the past year despite a wider net loss.
Iovance Biotherapeutics (IOVA) Stock Rallies on Analyst Upgrades, Amtagvi Momentum
Iovance Biotherapeutics (IOVA) stock rallied due to multiple analyst upgrades and strong commercial momentum for its flagship TIL therapy, Amtagvi, which saw preliminary full-year 2025 product revenue of $264 million. The company's pipeline advancements in soft tissue sarcomas and non-small cell lung cancer, along with improving gross margins and cash runway, have further bolstered investor confidence. Analysts maintain a largely positive outlook, anticipating significant upside driven by Amtagvi's sustained growth and broader label expansions.
Iovance Biotherapeutics jumps as analysts lift targets and short interest fuels momentum
Iovance Biotherapeutics (IOVA) saw a significant 12.0% stock increase, driven by bullish analyst updates, including price target revisions, following strong Q4 2025 results. Elevated short interest likely contributed to the rally through momentum-driven buying and short-covering. The company's upcoming investor conference presentations are also expected to draw further attention.
Iovance Biotherapeutics Shines with Positive Trial Outcomes and Upgraded Ratings
Iovance Biotherapeutics (IOVA) saw its stock surge by 12.77% after reporting promising results from its Lifileucel melanoma treatment, showing a 50% confirmed response rate in an early pilot trial. Analysts have responded positively, with firms like Barclays and Citizens upgrading the stock and increasing price targets due to strong Q4 revenue and anticipated operational improvements. Despite a net loss, the company's financial overview indicates strong liquidity and revenue growth, leading to investor optimism and a significant premarket share price increase.
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
Iovance Biotherapeutics, a high-risk penny stock, has developed Amtagvi, a cancer-fighting medicine showing commercial progress and potential for label expansions. While the company faces significant challenges with Amtagvi's complex manufacturing and administration process, successful navigation of these obstacles and entry into new markets could lead to substantial growth. Investors are advised to consider the heightened risks despite the stock's potential upside over the next decade.
Key facts: Iovance Biotherapeutics expands TIL therapy; UBS raises price target
Iovance Biotherapeutics (IOVA) is expanding its TIL therapy, Amtagvi, into new tumor types, reporting a 50% response rate in aggressive soft-tissue sarcomas and planning a 2026 trial. Consequently, UBS has raised its price target for Iovance Biotherapeutics from $2.00 to $4.00 per share.
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month High After Analyst Upgrade
Iovance Biotherapeutics (NASDAQ:IOVA) recently hit a new 52-week high after UBS Group raised its price target to $4.00, though maintaining a neutral rating. The company's stock traded as high as $4.38 on heavy volume. Analyst sentiment is mixed, with an average "Hold" rating and price targets ranging from $2.00 to $16.00, while the company reported better-than-expected Q4 EPS and revenue, analysts forecast a negative EPS for the current fiscal year.
UBS Raises PT on Iovance Biotherapeutics (IOVA)
UBS analyst David Dai raised the price target on Iovance Biotherapeutics (IOVA) from $2 to $4, while maintaining a Neutral rating, citing fundamental improvements in fiscal Q4 2025. The company reported strong quarterly revenue growth driven by the commercialization of AMTAGVI in advanced melanoma, with full-year product revenue reaching $264 million. Despite the positive outlook from UBS, the analyst noted uncertainty regarding the acceleration of Amtagvi's uptake.
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA)
This article provides a comprehensive overview of Iovance Biotherapeutics Inc. (NASDAQ: IOVA), including its current stock price, performance metrics, and financial analysis. It details the company's technical and fundamental ratings from ChartMill, its recent earnings report, and future growth forecasts from analysts. Additionally, the article outlines IOVA's company profile, its focus on cell therapies for cancer, and key products like Amtagvi.
RSU vesting boosts Iovance (NASDAQ: IOVA) CRO share holdings
Iovance Biotherapeutics' Chief Regulatory Officer, Raj K. Puri, reported the vesting of 5,470 restricted stock units (RSUs), converting into common shares on March 2, 2026. A portion of these shares (2,798) was withheld to cover mandatory taxes. Following these transactions, Puri directly holds 218,531 common shares and 21,878 RSUs that will vest in future installments.
Iovance Biotherapeutics’ TIL Therapy Showcases Promising Results
Iovance Biotherapeutics (IOVA) stock surged over 10% following promising clinical trial results for its TIL therapy, lifileucel, in advanced sarcoma patients and strong Q4 financial performance. The therapy showed a 50% response rate in pilot trials, leading to plans for a registrational trial in Q2 2026. Analysts from Barclays and Citizens upgraded their price targets for Iovance due to operational improvements and exceeding Q4 revenue expectations with $86.7M.
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 9.9% Higher After Analyst Upgrade
Iovance Biotherapeutics (NASDAQ:IOVA) saw its shares jump 9.9% after Citizens Jmp upgraded the stock from a market perform to a market outperform rating, setting a $5 price target. While analyst opinions are mixed, with Barclays raising its target to $11 (overweight) and Goldman Sachs maintaining a $2 target (sell), the consensus remains a "Hold" with an $8.63 target price. The company recently posted a modest EPS beat and significant revenue, and institutional ownership stands at approximately 77% due to increased stakes from major firms.
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
Iovance Biotherapeutics (IOVA) is considered a high-risk, high-reward investment, despite persistent losses and a precarious cash runway. The company's lead product, lifileucel (Amtagvi), is approved for advanced melanoma, and future growth is anticipated from potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions. The author, who has covered IOVA since 2020, remains bullish, projecting long-term upside potential of 200–300% by 2030, but cautions investors about significant safety, competition, and financial risks.
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 3,600 shares to two new, non-executive employees on February 19, 2026. These awards were made under the company's Amended and Restated 2021 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $2.85 per share and vest over a three-year period, subject to continued employment.
Assessing Iovance Biotherapeutics (IOVA) Valuation After Amtagvi Momentum And New Fast Track Designation
Iovance Biotherapeutics (IOVA) is garnering renewed attention following strong Q4 and full-year 2025 results, with significant revenue growth but also a net loss of US$390.98 million. The stock has seen a sharp increase in share price, leading to questions about whether the current market valuation fully reflects future growth prospects. While a narrative valuation suggests the stock is significantly undervalued at $3.86 compared to a fair value of $8.35, other metrics like the Price/Sales ratio indicate a premium relative to its fair ratio.
IOVA Receives Analyst Upgrade to Market Outperform by Citizens |
Iovance Biotherapeutics (IOVA) received an analyst upgrade from "Market Perform" to "Market Outperform" by Citizens' Reni J. Benjamin, with a new price target of $5.00 USD. This upgrade highlights a focused outlook on IOVA's future market potential, as the company prepares for potential U.S. regulatory approvals and commercialization of its autologous T-cell therapy for solid tumor cancers. The average target price from 10 analysts is $8.80, implying a significant upside from the current price.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Up 24.8% in February
Iovance Biotherapeutics (NASDAQ:IOVA) saw a significant increase in short interest in February, rising by 24.8% to 131,334,639 shares, representing 36.9% of its stock being sold short. This high short exposure is coupled with institutional ownership of around 77.03% and mixed analyst ratings, with an average target price of $8.63. The company recently exceeded earnings estimates for the quarter, reporting $0.18 EPS against a consensus of $0.22, and revenue of $86.77 million against $81.61 million.
IOVA: AMTAGVI drives robust growth as pipeline advances toward major milestones in lung and sarcoma
Iovance Biotherapeutics (IOVA) reported strong Q4 and full-year financials, primarily driven by the adoption of AMTAGVI and operational enhancements. The company is focused on expanding its treatment center network and advancing its pipeline, with significant clinical milestones anticipated in lung cancer and sarcoma, alongside the development of next-generation TIL therapies.
Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold
Wall Street Zen has upgraded Iovance Biotherapeutics (NASDAQ:IOVA) from a "sell" to a "hold" rating, citing the company's strong Q4 results which beat expectations, positive pipeline developments, and analyst upgrades. Despite the positive outlook, the stock faces volatility risks due to a high short interest of approximately 36.9% of its float. The company's lead product candidate, lifileucel, and its manufacturing ramp in Philadelphia are key drivers of its transition to a commercial-stage entity.
